<![CDATA[Genmab — Juni 2013]]>2nd line NHL, ORR 61% CR 37% http://www.proinvestor.com/r.php?u=http%3A%2F%2Fm.bloodjournal.hematologylibrary.org%2Fcontent%2Fearly%2F2013%2F05%2F21%2Fblood-2012-12-472027.abstract

]]>https://dev.proinvestor.com/forum/topic/451459/genmab-juni-2013RSS for NodeFri, 19 Jun 2026 00:15:08 GMTMon, 03 Jun 2013 04:04:49 GMT60<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 06:59:18 GMT]]>God ide at Jyske Quant koncentrerer sig om charms i stedet for Genmab. Så kommer deres "ekspertise" til rette http://www.proinvestor.com/investornyt/69776/pandora-jyske-bank-haever-anbefaling-til-kob-opd

]]>https://dev.proinvestor.com/forum/post/10072323https://dev.proinvestor.com/forum/post/10072323Thu, 27 Jun 2013 06:59:18 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 06:23:20 GMT]]>Præcis

]]>https://dev.proinvestor.com/forum/post/10072320https://dev.proinvestor.com/forum/post/10072320Thu, 27 Jun 2013 06:23:20 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 06:08:18 GMT]]>Omvendt beviser det vel bare, at Daratumumab ses som den værste konkurrent af konkurrenten

]]>https://dev.proinvestor.com/forum/post/10072321https://dev.proinvestor.com/forum/post/10072321Thu, 27 Jun 2013 06:08:18 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 06:06:22 GMT]]>Det bedste ville jo være, hvis MOM202 ikke viste effekt, for så havde Genmab lavet noget virkelig unikt. Men konkurrence er jo ikke altid dårlig, så der kommer også gode ting ud af det.

]]>https://dev.proinvestor.com/forum/post/10072322https://dev.proinvestor.com/forum/post/10072322Thu, 27 Jun 2013 06:06:22 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 06:01:05 GMT]]>Jeg tænker nu at det er ok for GEN, da Janssen må speede op. Og som du skriver er "vi" et år foran. Man kan jo heller ikke forvente eller tro at de andre bare sidder med hænderne i skødet

]]>https://dev.proinvestor.com/forum/post/10072324https://dev.proinvestor.com/forum/post/10072324Thu, 27 Jun 2013 06:01:05 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 05:41:26 GMT]]>Har lige skrevet et indlæg om det - ja den er ikke god. Nok den værste partner for Genmab/Janssen

]]>https://dev.proinvestor.com/forum/post/10072314https://dev.proinvestor.com/forum/post/10072314Thu, 27 Jun 2013 05:41:26 GMT<![CDATA[Reply to Genmab — Juni 2013 on Thu, 27 Jun 2013 05:39:49 GMT]]>Der bliver kamp til stregen på cd38 antistof markedet: http://www.reuters.com/article/2013/06/26/nj-morphosys-idUSnBw266538a+100+BSW20130626

]]>https://dev.proinvestor.com/forum/post/10072318https://dev.proinvestor.com/forum/post/10072318Thu, 27 Jun 2013 05:39:49 GMT<![CDATA[Reply to Genmab — Juni 2013 on Wed, 26 Jun 2013 13:09:19 GMT]]>Ja, men det går vel bare på, at fimaet i sin ansøgning slet ikke havde regnet på nogen ratio

]]>https://dev.proinvestor.com/forum/post/10072315https://dev.proinvestor.com/forum/post/10072315Wed, 26 Jun 2013 13:09:19 GMT<![CDATA[Reply to Genmab — Juni 2013 on Wed, 26 Jun 2013 04:09:47 GMT]]>tak for den artikel solsen - jeg bed mærke i, at Pazdur specifikt nævnte Hazard Ratio som del af grunden til at afvise...

]]>https://dev.proinvestor.com/forum/post/10072317https://dev.proinvestor.com/forum/post/10072317Wed, 26 Jun 2013 04:09:47 GMT<![CDATA[Reply to Genmab — Juni 2013 on Wed, 26 Jun 2013 03:59:40 GMT]]>
Link Preview Image
The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough

Dr. Richard Pazdur Maybe more than any other person alive, Richard Pazdur, the director of the Food and Drug Administration's Office of Oncology and Hematology Products, personifies the tension between the need to get new drugs to patients fast and the competing desire to make sure they are safe and effective [...]

favicon

Forbes (www.forbes.com)

]]>https://dev.proinvestor.com/forum/post/10072319https://dev.proinvestor.com/forum/post/10072319Wed, 26 Jun 2013 03:59:40 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 18:43:21 GMT]]>Dr. Janine Schuurman, Director Strategic Research at Genmab, will give a presentation on the efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange at the International Conference on monoclonal antibodies and cancer stem cells that will be held from 24th to the 26th June 2013

]]>https://dev.proinvestor.com/forum/post/10072316https://dev.proinvestor.com/forum/post/10072316Tue, 25 Jun 2013 18:43:21 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 15:42:23 GMT]]>Tak Plex, bestemt interessant

]]>https://dev.proinvestor.com/forum/post/10072313https://dev.proinvestor.com/forum/post/10072313Tue, 25 Jun 2013 15:42:23 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 15:34:20 GMT]]>https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=269125003&sourcecode=djn

]]>https://dev.proinvestor.com/forum/post/10072311https://dev.proinvestor.com/forum/post/10072311Tue, 25 Jun 2013 15:34:20 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 15:34:08 GMT]]>vil lige poste den her også: Bayer in $520 Million Pact With Seattle Genetics

]]>https://dev.proinvestor.com/forum/post/10072308https://dev.proinvestor.com/forum/post/10072308Tue, 25 Jun 2013 15:34:08 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 13:28:09 GMT]]>spændende

]]>https://dev.proinvestor.com/forum/post/10072309https://dev.proinvestor.com/forum/post/10072309Tue, 25 Jun 2013 13:28:09 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 12:52:01 GMT]]>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf FDA update på BTD mv.

]]>https://dev.proinvestor.com/forum/post/10072306https://dev.proinvestor.com/forum/post/10072306Tue, 25 Jun 2013 12:52:01 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 08:49:55 GMT]]>50 min inde hvis man ikke er meget dedikeret 🙂

]]>https://dev.proinvestor.com/forum/post/10072307https://dev.proinvestor.com/forum/post/10072307Tue, 25 Jun 2013 08:49:55 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 08:49:37 GMT]]>

]]>https://dev.proinvestor.com/forum/post/10072303https://dev.proinvestor.com/forum/post/10072303Tue, 25 Jun 2013 08:49:37 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 06:49:54 GMT]]>Ikke så meget nyt andet end vi ligeledes kan håbe daratumumab på sigt også kombineres med carfilzomib og Pomalidomide

]]>https://dev.proinvestor.com/forum/post/10072312https://dev.proinvestor.com/forum/post/10072312Tue, 25 Jun 2013 06:49:54 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 06:49:19 GMT]]>

]]>https://dev.proinvestor.com/forum/post/10072301https://dev.proinvestor.com/forum/post/10072301Tue, 25 Jun 2013 06:49:19 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 06:48:58 GMT]]>Lidt interessant at han siger, at det allerede nu ændrer praksis, at man bør tage et CD20 antistof i kombination med chlorambucil. Det er selvfølgelig konkurrenten, men måske allerede vi så småt vil begynde at se off label salg for Arzerra i first line - lidt har jo også ret

]]>https://dev.proinvestor.com/forum/post/10072305https://dev.proinvestor.com/forum/post/10072305Tue, 25 Jun 2013 06:48:58 GMT<![CDATA[Reply to Genmab — Juni 2013 on Tue, 25 Jun 2013 06:47:30 GMT]]>

]]>https://dev.proinvestor.com/forum/post/10072310https://dev.proinvestor.com/forum/post/10072310Tue, 25 Jun 2013 06:47:30 GMT<![CDATA[Reply to Genmab — Juni 2013 on Mon, 24 Jun 2013 19:22:52 GMT]]>Lyder godt

]]>https://dev.proinvestor.com/forum/post/10072297https://dev.proinvestor.com/forum/post/10072297Mon, 24 Jun 2013 19:22:52 GMT<![CDATA[Reply to Genmab — Juni 2013 on Mon, 24 Jun 2013 19:22:27 GMT]]>Konludere godt

]]>https://dev.proinvestor.com/forum/post/10072302https://dev.proinvestor.com/forum/post/10072302Mon, 24 Jun 2013 19:22:27 GMT